
News|Articles|February 13, 2019
Elzonris for Blastic Plasmacytoid Dendritic Cell Neoplasm
Author(s)Drew Boxler
Advertisement
ELZONRIS (tagraxofusp-erzs, Stemline® Therapeutics)
Indications: Treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older
Dosage: Intravenously at 2mcg/kg over 15 mins once daily on days 1 & 5 of a 21-day cycle
- First cycle recommended in inpatient setting, subsequent cycles either inpatient or other appropriate outpatient setting
Contraindications: None
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
The Drug Price Paradox: PBMs, Pharmacies, and the Path to Affordability
2
Zepbound Lowers Health Care Costs in Older Adults With Obesity
3
How mRNA and Protein-Based COVID-19 Vaccines Work
4
Ixekizumab, Tirzepatide Maintains Efficacy in Psoriatic Disease
5






































